Lumenis' Light Device FDA Approved for Treating Dry Eye
Lumenis announced that the FDA has granted De Novo authorization for the company's newest intense-pulsed-light device for improving the signs of dry eye due to meibomian gland dysfunction (MGD). Subsequent to the FDA approval, Lumenis is launching OptiLight. The company says OptiLight uses Lumenis’ patented Optimal Pulse Technology to "deliver a consistent, precise, and controlled light-based treatment of signs of dry-eye disease." Lumenis is hosting a virtual launch event for the OptiLight at 7 p.m. on May 13. To find out about the device and the event: click here.
New Ophthalmoscope Arrives
Hillrom says its new PanOptic Plus ophthalmoscope provides a viewing area that’s 20 times larger than the current Welch Allyn coaxial ophthalmoscope. The company says the new device features “Quick Eye Alignment” technology to help better direct a patient's gaze. Disc-alignment lights help the clinician direct and guide the patient's gaze, to help enable easier exams, Hillrom adds. Read more.
Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops, to Acquire U.S. Commercialization Rights to Simbrinza
Alcon announced the U.S. launch of the newest addition to its portfolio of dry-eye products – Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops. With its proprietary HydroBoost Technology, this new preservative-free eye drop provides extra moisture for patients with sensitive dry eyes, the company says. Learn more.
In addition, the company signed an agreement to acquire exclusive U.S. commercialization rights to the glaucoma combination drug Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. Read more.
Genentech to Present New Data at ARVO Annual Meeting
Genentech is presenting new data at the annual Association of Research in Vision and Ophthalmology meeting, being held virtually May 1 to 7. Presentations include:
• an analysis of the release rate of ranibizumab from its late-stage Port Delivery System with ranibizumab (PDS) and potency over time;
• new data from the Phase III clinical trials of faricimab in neovascular age-related macular degeneration and diabetic macular edema; and
• a look at a personalized health-care program that may be needed to predict how often ranibizumab injections are needed in patients with DME during the initial dosing period for optimal long-term treatment of retinal vein occlusion, and a study on predicting geographic atrophy lesion growth through deep learning.
In addition, several real-world studies will be presented on:
• new data on barriers to treatment adherence in nAMD and DME;
• long-term maintenance of driving vision for people with nAMD and DME following anti-VEGF treatment; and
• treatment patterns for nAMD patients following anti-VEGF therapy over five years.
Ocuphire Data to be Presented at ARVO Virtual Annual Meeting
Ocuphire Pharma says new data will be presented from PBPK modeling that confirmed the dosing strategy for the ongoing ZETA-1 Phase II trial in patients with diabetic retinopathy and diabetic macular edema. Read more.
Aerie Completes Enrollment of its Phase IIb Clinical Trial of AR-15512, Announces Presentations at the ARVO Annual Meeting
Aerie Pharmaceuticals completed patient enrollment for COMET-1, a Phase IIb clinical trial of AR-15512 (TRPM8 Agonist) (“AR-15512”) ophthalmic solution for the treatment of patients with dry eye. Read more.
In addition, the company will have poster presentations highlighting topics ranging from additional research findings on netarsudil to potential new product candidates. View the list of presentations.
Allegro to Present New Scientific Data at ARVO Annual Meeting
Allegro Ophthalmics announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the virtual meeting. View the list of presentations.
B+L to Present New Scientific Data at ARVO Meeting
Bausch + Lomb will present new scientific data for several products across its pharmaceutical, surgical and vision care portfolios, as well as from the company’s ongoing Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study. View the list of presentations.
Allergan to Share New Data at ARVO Annual Meeting
Allergan says it’ll present real-world evidence and patient-reported outcomes for products across its eye-care portfolio and pipeline at the virtual meeting. Learn more.
J&J Vision Introduces Acuvue Abiliti to Address Myopia in Children, Reinforces Sustainability Commitment
Johnson & Johnson Vision announced Acuvue Abiliti—a new brand for future products and services to help parents and eye-care providers address the growing prevalence and progression of myopia in children. Each annual purchase of an Abiliti product will provide a free comprehensive eye health exam to a child in need through Sight for Kids —a joint program from Johnson & Johnson Vision and the not-for-profit program from the Lions Clubs International Foundation. Read more.
In addition, the company signed a 10-year deal with JEA, a community-owned electric and water utility that serves Northeast Florida, to get 100 percent of its electricity for its global headquarters in Jacksonville, Fla., from solar power. Learn more.
Prevent Blindness Announces Recipients of Jenny Pomeroy Award, Declares May Ultraviolet Awareness Month
Prevent Blindness announced the recipient of the 2021 Jenny Pomeroy Award for Excellence in Vision and Public Health as R.V. Paul Chan, MD, MSc, MBA, FACS, professor and head of the Department of Ophthalmology and Visual Sciences at the University of Illinois at Chicago.
Additionally, the group announced the recipient of the second annual Rising Visionary Award as Shervonne Poleon, Vision Science Graduate Program student, University of Alabama at Birmingham. Read more.
In addition, Prevent Blindness declared May Ultraviolet Awareness Month as a way to educate the public about the dangers of UV light. View the patient resources.
Heidelberg and RetInSight to Offer AI-based OCT Fluid Quantification
Heidelberg Engineering GmbH and RetInSight GmbH plan to interface RetInSight’s AI-based fluid monitor application with the Heidelberg Engineering product portfolio, using “cloud exchange and application marketplace technologies.” They hope the fluid monitor application will facilitate early diagnosis and therapeutic guidance in common retinal diseases. Read more.
Foundation Fighting Blindness Appoints Dr. Gelfman as Chief Scientific Officer
Foundation Fighting Blindness appointed Claire M. Gelfman, PhD, as chief scientific officer, with a focus on research initiatives designed to accelerate new treatments and cures for inherited retinal diseases. Prior to joining the Foundation, Dr. Gelfman served as vice president of pharmaceutical development at Adverum Biotechnologies. Read more.
Complimentary CME Education Videos